FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761036170> ?p ?o ?g. }

• W2761036170 endingPage "v437" @default.
• W2761036170 startingPage "v437" @default.
• W2761036170 abstract "Background: BRAF and MEK inhibitors are approved for V600-mutated melanoma, and response rates of up to 70% are seen for patients with V600 mutations. Responses to targeted therapies have also been observed for a variety of non-V600 BRAF alterations. Thus, sensitive, accurate, and broad detection of BRAF alterations is critical to match patients with available targeted therapies. Methods: Pathology reports were reviewed for 385 consecutive melanoma cases (Mar 2016 - Mar 2017) with BRAF mutations or rearrangements identified using a hybrid-capture based next generation sequencing (NGS) assay during the course of clinical care. Results: Records of prior BRAF molecular testing were available for 79 (21%) cases, utilizing PCR (n = 30), Sanger sequencing (n = 13), IHC (n = 10), non-hybrid capture based NGS (n = 9), or other or unspecified methodology (n = 17). Of cases with BRAF V600 mutations 11/57 (19%) with available data were negative by prior BRAF testing, including 2/11 (18%) with confirmation that the same biopsy was tested. In cases with BRAF V600 mutations, there was no significant difference in mutant allele frequencies (median 35% vs. 40%, p = 0.25) or percentage of tumor nuclei (median 50% for both, p = 0.97) between samples with prior negative and prior positive results. Prior negative results were also identified in 16/20 (80%) cases with non-V600 mutations, two of which harbored multiple BRAF alterations [K601E (4), D594A/G/N (4), S467L (2), L584F (2), G464V, G466V, G469V, E586K, N581I, L597Q, A589_T599insT]. Two of 2 (100%) cases with activating BRAF fusions also had prior negative BRAF results. Clinical outcomes for a subset of patients will be presented. Conclusions: Despite approved companion diagnostics, significant variability exists in methods for BRAF testing in the clinical setting. Hybrid-capture based NGS identifies diverse activating mutations and fusions, including BRAF V600E, in a significant fraction of cases for which prior BRAF testing returned negative results. Given the proven clinical benefit in patients with BRAF alterations treated with match targeted therapies, hybrid-capture based NGS should be considered for patients with metastatic melanoma, particularly if other testing is negative. Legal entity responsible for the study: Foundation Medicine, Inc. Funding: Foundation Medicine, Inc. Disclosure: A. Wang, J.S. Ross, P.J. Stephens, S.M. Ali, A.B. Schrock, V.A. Miller: Employee with stock ownership in Foundation Medicine, Inc. All other authors have declared no conflicts of interest." @default.
• W2761036170 created "2017-10-20" @default.
• W2761036170 creator A5003919808 @default.
• W2761036170 creator A5004685117 @default.
• W2761036170 creator A5029117265 @default.
• W2761036170 creator A5029783882 @default.
• W2761036170 creator A5034870446 @default.
• W2761036170 creator A5035120516 @default.
• W2761036170 creator A5045110376 @default.
• W2761036170 creator A5051366611 @default.
• W2761036170 creator A5053602981 @default.
• W2761036170 creator A5062019987 @default.
• W2761036170 creator A5075566772 @default.
• W2761036170 creator A5088559019 @default.
• W2761036170 date "2017-09-01" @default.
• W2761036170 modified "2023-09-26" @default.
• W2761036170 title "Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing" @default.
• W2761036170 doi "https://doi.org/10.1093/annonc/mdx377.020" @default.
• W2761036170 hasPublicationYear "2017" @default.
• W2761036170 type Work @default.
• W2761036170 sameAs 2761036170 @default.
• W2761036170 citedByCount "0" @default.
• W2761036170 crossrefType "journal-article" @default.
• W2761036170 hasAuthorship W2761036170A5003919808 @default.
• W2761036170 hasAuthorship W2761036170A5004685117 @default.
• W2761036170 hasAuthorship W2761036170A5029117265 @default.
• W2761036170 hasAuthorship W2761036170A5029783882 @default.
• W2761036170 hasAuthorship W2761036170A5034870446 @default.
• W2761036170 hasAuthorship W2761036170A5035120516 @default.
• W2761036170 hasAuthorship W2761036170A5045110376 @default.
• W2761036170 hasAuthorship W2761036170A5051366611 @default.
• W2761036170 hasAuthorship W2761036170A5053602981 @default.
• W2761036170 hasAuthorship W2761036170A5062019987 @default.
• W2761036170 hasAuthorship W2761036170A5075566772 @default.
• W2761036170 hasAuthorship W2761036170A5088559019 @default.
• W2761036170 hasBestOaLocation W27610361701 @default.
• W2761036170 hasConcept C104317684 @default.
• W2761036170 hasConcept C121608353 @default.
• W2761036170 hasConcept C126322002 @default.
• W2761036170 hasConcept C143998085 @default.
• W2761036170 hasConcept C184235292 @default.
• W2761036170 hasConcept C2775934546 @default.
• W2761036170 hasConcept C2777658100 @default.
• W2761036170 hasConcept C2778472372 @default.
• W2761036170 hasConcept C2781230642 @default.
• W2761036170 hasConcept C501734568 @default.
• W2761036170 hasConcept C502942594 @default.
• W2761036170 hasConcept C54355233 @default.
• W2761036170 hasConcept C57074206 @default.
• W2761036170 hasConcept C71924100 @default.
• W2761036170 hasConcept C76818968 @default.
• W2761036170 hasConcept C86803240 @default.
• W2761036170 hasConceptScore W2761036170C104317684 @default.
• W2761036170 hasConceptScore W2761036170C121608353 @default.
• W2761036170 hasConceptScore W2761036170C126322002 @default.
• W2761036170 hasConceptScore W2761036170C143998085 @default.
• W2761036170 hasConceptScore W2761036170C184235292 @default.
• W2761036170 hasConceptScore W2761036170C2775934546 @default.
• W2761036170 hasConceptScore W2761036170C2777658100 @default.
• W2761036170 hasConceptScore W2761036170C2778472372 @default.
• W2761036170 hasConceptScore W2761036170C2781230642 @default.
• W2761036170 hasConceptScore W2761036170C501734568 @default.
• W2761036170 hasConceptScore W2761036170C502942594 @default.
• W2761036170 hasConceptScore W2761036170C54355233 @default.
• W2761036170 hasConceptScore W2761036170C57074206 @default.
• W2761036170 hasConceptScore W2761036170C71924100 @default.
• W2761036170 hasConceptScore W2761036170C76818968 @default.
• W2761036170 hasConceptScore W2761036170C86803240 @default.
• W2761036170 hasLocation W27610361701 @default.
• W2761036170 hasLocation W27610361702 @default.
• W2761036170 hasLocation W27610361703 @default.
• W2761036170 hasOpenAccess W2761036170 @default.
• W2761036170 hasPrimaryLocation W27610361701 @default.
• W2761036170 hasRelatedWork W2169071929 @default.
• W2761036170 hasRelatedWork W2617846385 @default.
• W2761036170 hasRelatedWork W2808608845 @default.
• W2761036170 hasRelatedWork W2888315487 @default.
• W2761036170 hasRelatedWork W2895954503 @default.
• W2761036170 hasRelatedWork W2940291671 @default.
• W2761036170 hasRelatedWork W3164187655 @default.
• W2761036170 hasRelatedWork W4246006194 @default.
• W2761036170 hasRelatedWork W4361946546 @default.
• W2761036170 hasRelatedWork W4361953392 @default.
• W2761036170 hasVolume "28" @default.
• W2761036170 isParatext "false" @default.
• W2761036170 isRetracted "false" @default.
• W2761036170 magId "2761036170" @default.
• W2761036170 workType "article" @default.